Epidemiologic evidence linking serum uric acid and incident hypertension is rapidly proliferating, and animal models of hyperuricemia have helped elucidate possible mechanisms for this relationship. 1 Furthermore, secondary analyses of clinical trial data suggest that the relationship between hypertension treatment and clinical outcomes is related to serum uric acid levels. 2, 3 The logical next step is to evaluate whether targeting serum uric acid prevents hypertension or hypertension-associated end-organ damage. We agree with Trachtman 4 that welldesigned, randomized, controlled trials should evaluate the efficacy of uric acid-lowering therapy in the prevention of hypertension.
